Compare · BSX vs NMTC
BSX vs NMTC
Side-by-side comparison of Boston Scientific Corporation (BSX) and NeuroOne Medical Technologies Corporation (NMTC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and NMTC operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.39B, about 2427.0x NMTC ($29.8M).
- Over the past year, BSX is down 51.3% and NMTC is down 1.1% - NMTC leads by 50.2 points.
- BSX has been more active in the news (12 items in the past 4 weeks vs 3 for NMTC).
- BSX has more recent analyst coverage (25 ratings vs 4 for NMTC).
- Company
- Boston Scientific Corporation
- NeuroOne Medical Technologies Corporation
- Price
- $48.71+0.31%
- $3.46+0.87%
- Market cap
- $72.39B
- $29.8M
- 1M return
- -13.91%
- -22.07%
- 1Y return
- -51.31%
- -1.09%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 12
- 3
- Recent ratings
- 25
- 4
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corporation operates as a medical technology company. It focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and other related brain related disorders. NeuroOne Medical Technologies Corporation has a strategic partnership with RBC Medical Innovations to develop and manufacture a radiofrequency generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest NMTC
- SEC Form SD filed by NeuroOne Medical Technologies Corporation
- SEC Form SD filed by NeuroOne Medical Technologies Corporation
- NeuroOne Medical Technologies Corporation filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by NeuroOne Medical Technologies Corporation
- NeuroOne Medical Technologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- NeuroOne Medical Technologies Corporation filed SEC Form 8-K: Other Events
- NeuroOne Medical Technologies Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form SCHEDULE 13G filed by NeuroOne Medical Technologies Corporation
- NeuroOne Medical Technologies Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form 4 filed by Mills Jason Richard